BeOne Medicines price to sales ratio ONC

Market value divided by revenue over the last twelve months, since 2018.

Today, Oct 23, 2026: 7.0×
8-year median: 16.9×
Against its 8-year history: 22nd; percentile: 0 is its lowest day, 100 its highest
8-year range: 5.1× to 130×
Peer median: 7.3×

BeOne Medicines' price to sales ratio is 7.0× as of Oct 23, 2026.

That is below its 8-year median of 16.9×, lower than on 78% of days in the last 8 years.

Over that time it ranged from 5.1× in Jun 2026 to 130× in Feb 2021.

The median for 10 biotech stocks of a similar size is 7.3×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	7.0×	5.1×	8.1×
2025	7.0×	5.7×	8.3×
2024	5.8×	5.4×	8.4×
2023	8.6×	8.3×	22.5×
2022	18.3×	12.9×	22.9×
2021	23.9×	23.7×	130×
2020	88.5×	21.5×	127×
2019	23.6×	16.6×	54.3×
2018	51.6×	20.7×	57.7×

Against its peers

Companies in Biotechnology nearest BeOne Medicines' size, closest first, today.

Company	Price to sales ratio
ONCBeOne Medicines	7.0×
ALNYAlnylam Pharmaceuticals	6.2×
UTHRUnited Therapeutics	8.0×
INCYIncyte	4.0×
REGNRegeneron Pharmaceuticals	5.3×
EXELExelixis	6.6×
NBIXNeurocrine Biosciences	4.3×
HALOHalozyme Therapeutics	8.6×
VRTXVertex Pharmaceuticals	10.6×
TECHBIO-TECHNE	9.4×
RGENRepligen	12.7×
Peer median	7.3×

Where BeOne Medicines ranks

#34of 63Biotech stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on BeOne Medicines

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.